echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP-phosphorylated tau and neurofilament light chain protein can complement each other's strengths and predict cognitive ability

    JNNP-phosphorylated tau and neurofilament light chain protein can complement each other's strengths and predict cognitive ability

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Alzheimer’s disease (AD) is characterized by misfolded amyloid β (Aβ) and phosphorylated tau (p-tau) proteins, which are found in senile plaques outside the cell and neurofibrillary tangles inside neurons, respectively.
    The brain piles up

    .

    A clear diagnosis of AD requires confirmation of these pathological features at autopsy, but due to the development of reliable cerebrospinal fluid (CSF) and PET measurements of Aβ and tau burden, it has been possible to accurately determine the diagnosis of AD in vivo
    .
    These markers have good diagnostic accuracy in the clinical population, but they involve invasive lumbar puncture or exposure to ionizing radiation, and require special environments and equipment

    .

    diagnosis

    As the clinical use of AD-modifying drugs that reduce Aβ accumulation has recently become a reality, a widely applicable and accurate risk-adaptive, personalized prevention and treatment method has become imperative
    .
    The blood-based biomarker algorithm may be crucial because it is easy to measure and cost-effective compared to current gold standard assessments

    .
    Recent work has shown that in clinical and population-based cohorts, Aβ42/40, p-tau181, p-tau217 (but not total tau, (t-tau)) and neurofilament light chain (NfL) based on ultra-sensitive detection technology ) The new measurement method has achieved good results;

    prevention

    However, many aspects of blood-based measurement methods still need to be further studied, including longitudinal trajectories measured in the same human body and their relationship with cognitive decline and changes in PET tau load
    .

    Includes longitudinal trajectories measured in the same person and their relationship with cognitive decline and changes in PET tau load
    .
    Includes longitudinal trajectories measured in the same person and their relationship with cognitive decline and changes in PET tau load
    .

    In this way, Boris Stephan Rauchmann of the University of Munich and others used the National Institute of Aging-Alzheimer’s Association (NIA-AA) research framework to compare biomarkers with different biomarkers based on the classification system of biomarkers.
    Characteristic groups

    .

    The main purpose is to explore the changes of p-tau181 and NfL measured in plasma in the NIA-AA biomarker group over time, and to explore the relationship between the baseline peptide concentration and time trajectory and memory performance, tau and PET Aβ accumulation after 6 years How
    .


    They used 865 ADNI cohort participants, used the established AD cut-off point of Aβ42, total tau and p-tau181, classified the subjects according to NIA-AA, and divided the markers into Aβ deposition (A) and tau pathology ( T) and neurodegeneration (N)
    .
    Analysis of variance was used to compare plasma biomarker data between ATN groups

    .



    The linear mixed-effects model was used to obtain the change rate of p-tau181 and NfL over time, and the comparison was made between the ATN groups
    .
    Linear regression analysis was used to study the relationship between baseline plasma biomarker concentration and rate of change and future PET tau and Aβ load and cognitive performance

    .


    They found that the plasma concentrations of P-tau181 and NfL increased along the AD lineage, but only NfL showed a greater rate of change in AD patients compared to the control group
    .
    Cognitive performance is related to NfL in all subgroups, while it is only related to P-tau181 in the AD pedigree
    .

    The plasma concentrations of P-tau181 and NfL increased along the AD lineage, but only NfL showed a greater rate of change in AD patients compared to the control group
    .
    The plasma concentrations of P-tau181 and NfL increased along the AD lineage, but only NfL showed a greater rate of change in AD patients compared to the control group
    .

    The baseline concentration of the two plasma markers can predict the load and cognitive performance of PET Aβ and tau
    .
    The rate of change of NfL predicts future PET tau and cognitive performance

    .

    The important significance of this study is that it is found that the performance of P-tau and NfL in the same person is different over time, so it may provide complementary diagnostic information
    .

    It is found that the performance of P-tau and NfL in the same person is different over time, so it may provide complementary diagnostic information
    .
    It is found that the performance of P-tau and NfL in the same person is different over time, so it may provide complementary diagnostic information
    .


    Original source:
    Rauchmann BS, Schneider-Axmann T, Perneczky R; Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
    J Neurol Neurosurg Psychiatry.
    2021 Jun 29 :jnnp-2020-325537.
    doi: 10.
    1136/jnnp-2020-325537.
    Epub ahead of print.
    PMID: 34187867.





    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.